Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that male patients with androgenetic alopecia had significantly higher aldosterone levels and blood pressure compared to controls, suggesting a possible link between AGA and hypertension.

This study found that Aminexil clinical 5 significantly reduced hair loss in men and women with mild alopecia and was well tolerated with high subject satisfaction.

In this study, researchers observed that men with androgenetic alopecia had a higher prevalence of metabolic syndrome compared to those without alopecia, which may warrant early screening for metabolic syndrome to prevent coronary artery disease, despite the study's small sample size.

This study found that Clitocybin A from Clitocybe aurantiaca significantly increased the proliferation of immortalized rat dermal papilla cells, suggesting potential hair growth-promoting effects in a laboratory setting.

This study found that Korean patients with androgenetic alopecia had higher rates of cardiovascular diseases and related risk factors than those without the condition, with variations by severity and type of hair loss.

This study found that N-acetyl-cysteine alone or combined with minoxidil improved hair parameters in men with early-onset androgenetic alopecia, with tolerable side effects.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

Malassezia species may contribute to hair loss in AGA patients.

This study found that men with more advanced androgenetic alopecia had increased epicardial fat thickness, suggesting a potential link to coronary risk.

This review discusses the characteristics and management of adolescent androgenetic alopecia, noting a lack of FDA-approved treatments and reporting no new clinical results.

This study found that kaempferol may stimulate hair growth in androgenetic alopecia by enhancing dermal papilla cell function and reducing dihydrotestosterone-induced damage, showing comparable efficacy to finasteride in a mouse model.

This study found that the treatment group experienced a higher average increase in hair counts than the placebo group, but the difference was not statistically significant.

This study found that azelaic acid entrapped in transethosomes exhibited enhanced antidermatophyte activity and improved treatment outcomes in guinea pig models of dermatophytosis compared to free azelaic acid.

This review found that androgenetic alopecia may be associated with increased risks of cardiovascular disease, metabolic disorders, and mental health impacts, suggesting its potential as a biomarker for systemic conditions.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This study reported that educating patients about androgenetic alopecia treatment options increased awareness of the ineffectiveness of hair cosmetics and their perceived cost.

This study found that androgenetic alopecia in Chinese college students is more prevalent in males and is significantly associated with rosacea, with clinic patients experiencing a higher disease burden.

AGA treated with finasteride, minoxidil, and hair transplantation.

This study assessed the combination of compound glycyrrhizin and conventional treatments for alopecia areata and found it effective for promoting hair regrowth while being safe with mild adverse effects, based on a systematic review and meta-analysis of randomized controlled trials.

In this case report, a 28-year-old male with androgenetic alopecia showed improved hair density and shaft thickness after four monthly sessions of autologous growth factor concentrate injections, with no adverse effects and high patient satisfaction, suggesting the treatment’s promise as a safe and effective option.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This review discusses the potential benefits of using topical caffeine products for treating androgenic alopecia but reports no new clinical findings; the authors highlight caffeine's possible positive effects based on existing studies.

This study found a statistically significant association between androgenetic alopecia and coronary artery disease in men, with higher grades of alopecia, especially involving the vertex, indicating a greater risk.

This study found that males with androgenetic alopecia had a higher risk of coronary artery disease, with significant differences in several lipid and blood pressure markers compared to controls.

This report documents the first known case of acute inflammatory demyelinating polyneuropathy potentially linked to pegylated interferon-alpha 2a in a woman undergoing treatment for chronic hepatitis C.

This review discusses the criteria for evaluating treatments for androgenetic alopecia and emphasizes the importance of shared decision-making, noting no treatment currently meets all desired criteria of efficacy, safety, affordability, and ease of use.

In this study, higher expression of PEDF was observed in hair follicles from balding regions in AGA patients, suggesting that targeting PEDF could be a promising approach for treating androgenetic alopecia.

This study found that moderate to severe androgenetic alopecia is an independent predictor of increased mortality risk from diabetes mellitus and heart disease in both sexes.

This expert panel review developed consensus recommendations for managing androgenetic alopecia in Canadian adults, endorsing seven interventions like oral and topical medications and platelet-rich plasma.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.